日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
China
Home / China / Health

Approval sped up for pediatric drugs

By WANG XIAOYU | China Daily | Updated: 2022-06-02 09:19
Share
Share - WeChat
[Photo/VCG]

China's top drug regulator has sped up approval for pediatric medications in recent years, the National Medical Products Administration said on Tuesday.

The administration has granted pediatric urgently-needed drugs priority when it comes to reviews, and has set up green channels and designated personnel to supervise approval procedures to reduce review times as much as possible.

The development of pediatric drugs is even more contentious and time-consuming than that of drugs for adults due to obstacles and uncertainties associated with rolling out clinical trials or devising dosages.

Last year, 47 pediatric drugs or medications previously not eligible for children's use were granted market approval, among them inhalants, rotavirus vaccines and traditional Chinese medicines.

"The number of newly approved drugs was far higher than the previous year," the administration said, adding that the number of applications and approvals for pediatric drugs has been trending upward in recent years.

Between January and April, the administration completed 30 approval procedures for 21 pediatric drugs, eight of which had qualified for priority review.

"The completed workload for pediatric drug evaluation increased by 90.91 percent over the same period last year," the administration said.

In the meantime, it has been importing new pediatric drugs in urgent demand.

Some of the newly approved products include an infusion for spinal muscular atrophy and another for treating Fabry disease, a rare genetic condition that causes a buildup of fats in the bloodstream.

On May 21, a 10-year-old girl in Chongqing received Replagal, the drug for treating Fabry disease, at the Children's Hospital of Chongqing Medical University.

The drug was selected for a list of medications qualified for expedited review and approval in 2018 and granted market approval in China in August, 2020. In October last year, the medication was added onto the national drug reimbursement list.

Wang Mo, head of the nephrology department at the hospital, said during an interview with People's Daily that each round of treatment required two injections, which would have cost 6,000 yuan ($896).

With reimbursement, the girl's family only needed to cover less than 3,000 yuan, she said.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
 
主站蜘蛛池模板: 国产成人偷拍 | 91精品国产91久久久久久 | 欧美精品久久久久久久久老牛影院 | 在线观看亚洲专区 | 久久www免费人成看片高清 | 亚洲视频中文字幕 | www.9p234.com | 亚洲国产天堂久久综合9999 | 国产精品国产精品国产专区不卡 | 影音先锋中文字幕在线 | 日本夜爽爽一区二区三区 | 欧美中文在线观看 | 国产在线激情视频 | 欧美成人另类人妖 | 欧美视频三区 | 91成人免费看 | 三极片免费看 | 亚洲成人一区二区 | 亚洲一区二区三区视频 | 日韩欧美国产精品 | 国产麻豆 | 国内精品免费视频 | 国产色婷婷视频在线观看 | 久久精品蜜芽亚洲国产a | 国产日韩欧美精品 | 天堂va在线高清一区 | 精品一区二区三区在线视频 | 久久婷婷综合中文字幕 | 久996视频精品免费观看 | 亚洲国产精品综合久久网络 | 亚洲国产一区二区三区四区色欲 | 欧美a区| 播播成人网 | 久久人人爽人人爽 | 国产麻豆传媒视频 | 波多久久夜色精品国产 | 国产电影一区二区 | 精品免费视频 | 精品国产免费一区二区三区 | 国产精品99999999 | 成人欧美一区二区三区在线播放 |